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Abstract 
Despite the presence of monounsaturated fatty acids 
(MUFA) in the usual diet, these fatty acids may also 
be synthesized de novo from saturated fatty acids 
(SFA) through enzymatic desaturase activity 
(Arregui et al., 2012). Stearoyl-CoA desaturase 
(SCD)1 and SCD5 isozymes have been identified in 
human. SCD1 or ?9 desaturase is predominantly 
expressed in adipose tissue, meibomian, harderian 
and preputial glands. This enzyme is highly induced 
in response to high carbohydrate diet (Mauvoisin 
Mounier, 2011). It has been proven that the elevated 
levels of SCD1 are associated with obesity, 
metabolic disorders and malignancies. Altogether, 
these findings propose SCD1 as a new therapeutic 
target. 
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Identity 
Other names: PRO1933, FADS5, MSTP0081, 
SCDOS, SCD1 
HGNC (Hugo): SCD 
Location: 10q24.31 
Local order 
Locus tag (NCBI), PRO1933. 5'- 100347015 - 
100364831 -3'; strand: (-). The human SCD1 gene is 
centromeric to LINC00263 (long intergenic non-
protein coding RNA 263) and telomeric to PKD2L1 
(polycystic kidney disease 2-like 1). 
DNA/RNA 
Note 
SCD1 gene encodes an enzyme that serves as a fatty 
acid synthesizing enzyme and mostly produces oleic 
acid from stearic acid. Transcripts with alternative 
polyadenlyation and sizes 3.9 and 5.2 kb has been 
detected for this gene. 
Description 
SCD1 gene is located on chromosome 10q24.31, 
spans approximately 24 kb and has 6 exons and is 
mostly expressed in white adipose tissue and the 
liver (Arregui et al., 2012). The exon 1 is only 324bp 
while the exon 6 encodes for around 2 kb 3'-
untranslated region (Mauvoisin & Mounier, 2011). 
Schematic representation of the genomic organization of exons of the SCD1 gene (17817 bp). 
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A schematic representation of the domain structure of SCD1 protein (359 amino acids total), which consists of cytoplasmic, 




The critical region for promoter activity is located 
between nucleotides 496-609 upstream of the 
translation start site. CCAAT box is identified as an 
important cis-element binding site in this region 
(Zhang, Ge, Tran, Stenn, & Prouty, 2001). Different 
transcription factors such as SREBP-1c, LXR, 
PPAR-a, C/EBP-a, NF-1, NF-Y, AP-1, Sp1, TR and 
PGC1-a bind to SCD1 promoter controlling the 
expression level of SCD1 (Mauvoisin & Mounier, 
2011). 
Pseudogene 
Pseudogene of this gene is located on chromosome 
17 at 17p11.2. The SCD1 pseudogene has two 
premature in-frame stop codons and is 
transcriptionally inactive (Zhang, Ge, Parimoo, 
Stenn, & Prouty, 1999). 
Protein 
Note 
SCD1 is an iron containing enzyme which catalyses 
the oxidation of palmitoyl-CoA and stearoyl-CoA in 
?9 position to produce corresponding derivatives 
palmitoleoyl-CoA and oleoyl-CoA, respectively. 
Formation of cis double bond is mediated by 
electeron-transfer proteins sequentially NADH-
cytochrome b5 reductase, cytochrome b5 and SCD. 
Electrons flow from NADPH source to cytochrome 
b5 reductase and to the cytochrome b5 as the direct 
electron donor to SCD1 and finally to O2 which is 
reduced to H2O. The rate-limiting step in this 
reaction is desaturase (Zhang et al., 1999). 
Description 
SCD1 contains four transmembrane domain which 
two NH2 and COOH terminals are located in 
cytoplasmic side. The single cytoplasmic loop and 
COOH terminus collectively contain eight Histidine 
residues forming His box and bind to iron at the 
center of catalytic site of desaturase. Two ER 
luminal loops are relatively smaller than cytosolic 
loop which contain two of the three conserved His 
motifs. Purified SCD1 remains in 37kDa band on 
SDS-PAGE and His segments located in 119, 156 
and 296 provide ligands for nonheme iron within the 
catalytic site of the SCD1 (Paton & Ntambi, 2009). 
Expression 
SCD1 promoter contains several transcription factor 
binding sites that are involved in positive or negative 
regulation of SCD1 gene. Sterol regulatory element-
binding proteins (SREBP) are a group of 
transcriptional factors belonging to helix-loop-helix 
leucine zipper family and are responsible for 
regulating cholesterol, fatty acids and triglyceride 
synthesis enzymes (Miyazaki et al., 2004). SREBP-
1a is the dominant isoform of SREBP in human 
cultured cells and induces SCD1 gene expression 
(Shimomura, Shimano, Horton, Goldstein, & 
Brown, 1997). Furthermore, Liver X Receptors 
(LXR) including LXR-? and LXR-? serve as positive 
inducers of SCD1 gene (Peter et al., 2008). 
Therefore, PPARa in combination with LXR causes 
elevation in the levels of SCD1 gene expression 
(Hebbachi, Knight, Wiggins, Patel, & Gibbons, 
2008). The involvement of PPARa in transcriptional 
regulation of SCD1 has also been reported in human 
pancreatic cells. Specifically, MEK/ERK1/2- and 
EGFR-dependent pathways exerted inhibitory effect 
on the expression and activity of SCD1 in these cells, 
possibly via PPARa activation (Byagowi et al. 
2015). 
Localisation 
SCD1 is anchored to reticulum endoplasmic 
membrane (Liu, Strable, & Ntambi, 2011). 
Function 
SCD1 is a rate-limiting enzyme which converts SFA 
to MUFA mainly oleate and palmitate causing high 
contents of MUFA in membrane phospholipids, 
triclycerides and cholesterol esters (Matsui et al., 
2012). 
Homology 
Two SCD isoforms, SCD1 and SCD5 have been 
identified in human. SCD1 has a high degree of 
homology with SCD5 in human genome. Four SCD 
isoforms, SCD1 to SCD4 have also been identified 
in mouse. SCD1 shares about 85% amino acid 
identity with all 4 mouse SCD isoforms, as well as 
with rat SCD1 and SCD2. In contrast, SCD5 shares 
limited homology with the rodent SCDs and appears 
to be unique to primates (Wang et al., 2005). 
[supplied by OMIM, Mar 2008]. (Leung & Kim, 
2013). 
Mutations 
SCD1 gene is located on 10q24.31 position and 
shows different sequence polymorphisms (SNPs). 
Among these polymorphisms, rs3071, rs1502593 
and rs10883463 SNPs have a higher degree of mean 
allele frequency (MAF) and are more studied. These 
SNPs has been implicated in multiple aspects of lipid 
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metabolism. Also, rare alleles of rs10883463, 
rs7849, rs2167444, and rs508384 are associated with 
decreased BMI and improved insulin sensitivity 
(Abdelmagid et al., 2013; Arregui et al., 2012; Gong 
et al., 2011). 
Implicated in 
Breast cancer 
Over-expression of SCD1 is associated with 
enhanced growth rate of breast cancer cell lines and 
shorter overall survival and relapse-free survival 
(RFS) in breast cancer patients (Holder et al., 2013).  
Furthermore, it is demonstrated that high 
desaturation index has a negative correlation with 
the risk of breast cancer (Chajs et al., 1999). Down-
regulation of SCD1 by specific siRNA also leads to 
reduction of proliferation rate, cell cycles' gene 
expression and phosphorylation state of ERK1/2 
(Mauvoisin, Charfi, Lounis, Rassart,  Mounier, 
2013).  
On the other hand, Mohammadzadeh et al. study 
revealed that inhibition of SCD1 by a selective 
inhibitor causes significant alteration in fatty acid 
composition of tissue cultured breast carcinoma in 
comparison to normal-appearing breast tissues and 
this has been attributed to the different level of SCD1 
activity (Mohammadzadeh et al., 2014). 
Hepatocellular carcinoma 
Bansal et al. study indicated that SCD1 was 
significantly over-expressed in hepatocellular 
carcinoma (HCC) tissues in comparison to adjacent 
normal tissues and in HCC cell lines including 
HepG2, Hep3B and PLC/PLF/5.  
Furthermore, the level of SCD1 was negatively 
associated with tumour differentiation grade. 
Treatment of liver cancer cell lines with different 
panel of chemotherapeutic agents also caused over 
expression of SCD1 in a time dependent manner and 
the consequent resistance to drug induced apoptosis.  
It is also demonstrated that inhibition of SCD1 by 
genetic manipulation or chemical inhibitors leads to 
elevated sensitivity to chemotherapeutic agents 
(Bansal et al., 2013). 
Colorectal cancer 
Recent studies have revealed that cell death is 
induced in colorectal cancer cells following SCD1 
inhibition.  
This effect is most possibly mediated through 
caspase 3 activity and PPAR-cleavage (Minville-
Walz et al., 2010). Other studies have also reported 
that HTC116 colon cancer cell lines are susceptible 
to SCD1 depletion and subsequent decreased cell 
viability (Mason et al., 2012). 
Esophageal cancer 
Shuai Guo et al. study has shown SCD1 up-
regulation in esophageal cancerous tissues in 
comparison to adjacent normal tissues. Furthermore, 
tissue lipid distribution analysis revealed that 
MUFA/PUFA ratio is elevated in cancerous 
microenvironment due to over activation of SCD1 
(Guo, Wang, Zhou,  Li, 2014). 
Gastric cancer 
Roongta et al. reported SCD1 inhibition causes 
tumour growth delay in a xenograft model in nude 
mice (Roongta et al., 2011). 
Obesity 
Obesity and type 2 diabetes are highly associated 
with abnormal lipid metabolism and 
intramyocellular accumulation of triglycerides. 
Hulver et al reported that SCD1 is up-regulated in 
skeletal myocytes of obese individuals. 
Overexpression and overactivity of SCD1 is linked 
to lower fatty acid ?-oxidation rate and elevation of 
triglyceride and MUFA synthesis in extremely obese 
population (Hulver et al., 2005). 
Lipotoxicity and inflammation 
Lipotoxicity is a common characteristic of diabetes 
and metabolic syndrome. It is defined by the 
elevation of intracellular fatty acid metabolites 
including diacylglycerol and ceramides leading to 
endoplasmic reticulum (ER) stress. This cellular 
stress triggers phosphorylation of insulin receptor 
substrates in serine/threonine residues and activation 
of the nuclear factor (NF)-?B pathway (Eizirik, 
Cardozo,  Cnop, 2008). Such signalling pathways 
induce an acute inflammatory response with 
cytokines secretion and diminished down-stream 
events of insulin receptor signalling cascade 
resulting in low-grade inflammatory state (Peter et 
al., 2009). Among SFA, stearate and palmitate have 
a high lipotoxicity potential to induce inflammation, 
ER stress and insulin resistance (Staiger et al., 2006). 
SCD1 enzyme desaturases stearate and palmitate to 
less toxic monounsaturated forms oleate and 
palmitoleate (Peter et al., 2008). Overexpression of 
SCD1 is also associated with increased triglyceride 
storage and decreased palmitate-induced apoptosis, 
ceramide and diacylglycerol synthesis, as well as 
insulin resistance (Pinnamaneni, Southgate, 
Febbraio,  Watt, 2006). 
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